Introduction
Rheumatoid arthritis is caused by a complex mechanism involving synoviocytes, osteoclasts and immune cells that are interconnected via cytokines and other signalling molecules. Effective medical treatment for joint destruction in rheumatoid arthritis is lacking because the molecular mechanisms leading to joint destruction are incompletely understood. However, it is known that cytokinemediated immunity and perturbations in the balance of effector cells at the disease site play a crucial role in rheumatoid arthritis pathogenesis. Cellular and cytokine inhibitors have been used for treatment purposes. Increasing evidence has revealed the importance of IL-17, an activated T cell-derived inflammatory cytokine, and IL-23 in the pathogenesis of rheumatoid arthritis. The role of IL-17 has been of particular interest, as IL-17 affects the differentiation and activation of pathogenic osteoclasts. Cellularly, the key features of rheumatoid arthritis include disturbance of the Th17/Treg balance and plasticity, deregulated Th17 responses and the reduction or absences of Treg cells. Recent developments in the area of CD4 + T-cell differentiation, together with experimental and preclinical findings on inhibitors of the IL-17 pathway and the use of Treg cell-based therapy, indicate that CD4 + effector cells, TH17 and Treg, could be effective targets for restoring immune tolerance. In this critical review, we summarise the progress in our understanding of the role of IL-23, IL-17 and CD4 + T-cell differentiation into specialised effectors, focusing on Th17 and Treg cells, in the pathogenesis of rheumatoid arthritis.
Conclusion
Pathogenesis of rheumatoid arthritis is slow and complex. Cytokines and cell-mediated immunity are involved in irreversible bone and cartilage destruction. Cytokine levels and the Treg/Th17 balance might be relevant
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease. In RA, inflammation usually affects multiple peripheral joints, but other tissues and organs are also involved. RA can affect any joint that has a synovial-fluid-filled joint cavity lined by a synovial membrane and regions in which cartilage overlies the bone 1 . Komatsu et al. 2 suggested that the clinical progression of RA involves three stages in the progression from an immune response to bone destruction. These are summarised as follows:
• 
Discussion
Role of the IL-23p19/IL-17 axis in RA IL-23p19 and IL-17 correspond to a new axis that drives immune activation and chronic inflammation through the differentiation and activation of Th17 cells. Both IL-17 and IL-23 were found to be present in the synovial fluid, synovial tissue and serum of patients with RA, whereas they were absent in healthy joints and other types of arthritis such as osteoarthritis 7 . The significant role of IL-17 in RA is highlighted by the current success of clinical trials with neutralizing antibodies specific for IL-17 8 . Blocking IL-17 during the reactivation of antigen-induced arthritis diminishes joint swelling, joint inflammation and bone erosion 9 . This cytokine has diverse immune functions, including activation of synovial fibroblasts to produce IL-6, IL-8 and vascular growth factors, chemoattraction of neutrophils, stimulation of the expression of the receptor activator of NF-κB ligand (RANKL) (a factor that is crucial for osteoclastogenesis) and mediation of direct pro-osteoclastogenic effects 10, 11 . Th 17/RANKL is the bridge between the immune and skeletal systems and leads to bone destruction in RA Bone destruction in RA is mainly attributable to the abnormal activation of osteoclasts. Osteoclasts are multinucleated cells of the monocyte/ macrophage lineage that degrade bone matrix and dynamically remodel the skeleton 13, 14 . The generation of osteoclasts is physiologically supported by mesenchymal cells such as osteoblasts, which provide essential signals for differentiation of the osteoclast lineage: macrophage colony-stimulating factor, RANKL and costimulatory signals for RANKL 15 . Osteoprotegerin (OPG) is a soluble decoy receptor for RANKL that blocks the pro-osteoclastogenic activity of RANKL. In inflammatory arthritis, the RANK/RANKL pathway is activated, resulting in deregulated bone remodelling. In patients with RA, the synovial tissues exhibit an increased ratio of RANK:OPG mRNA expression, indicating that pro-osteoclastogenic conditions dominate the microenvironment of RA-affected joints 16 . There is accumulating evidence that bone destruction in RA is driven by the Th17-cell-mediated induction of RANKL expression in synovial cells, which together with inflammatory cytokine production, stimulates the differentiation and activation of osteoclasts and therefore bone resorption 17 . IL-17 has been shown to increase the spontaneous production of matrix metalloproteinases by synoviocytes and activate chondrocytes to inhibit matrix synthesis and induce cartilage matrix degradation 18 . In mice, intra-articular injection of IL-17 into the knee joint results in joint inflammation and damage. In addition, it is well documented that blocking IL-17/IL-17R signalling is effective at controlling local and systemic inflammatory manifestations, lowering the level of RANKL and blocking cartilage and bone destruction 19 . These findings indicate that Th17 and RANKL bridge the skeletal and immune systems and have led to a new research field called osteoimmunology 13 . This interdisciplinary field is important for the treatment of diseases associated with the bone and immune systems. + T cells impairs differentiation into Th17 cells and production of IL-17A and limits the development of experimental autoimmune encephalomyelitis 25 . By contrast, the IL-2/STAT5 pathway is essential for the maintenance of homeostasis and for the competitive fitness of Treg cells, and it suppresses differentiation into Th17 cells 24 . Treg cells and Th17 effectors arise in a mutually exclusive fashion, depending on whether they are activated in the presence of TGF-β or TGF-β plus IL-6. In a healthy individual or in the absence of any inflammatory trigger, TGF-β produced in the immune system will suppress the generation of Th17 effector cells and induce Foxp3 + Treg cells and thereby maintain self-tolerance. However, during infection or inflammation, IL-6 produced by the activated innate immune system suppresses the generation of TGF-β−induced Treg cells and induces a pro-inflammatory T-cell response predominated by Th17 cells 26 . Although IL-6 plays a critical role in the development of the Th17 response and in the inhibition of Treg functions, it is also thought that additional control steps must exist during this process and that other cytokines might participate in differentiation into Th17 cells.
Perturbations in the balance between Treg and Th 17 cells lead to osteoclastogenesis and bone destruction
The plasticity between the Th cell subsets is worth mentioning here. It was thought for many years that all CD4 + T cells (Th1, Th2, Th17 and Treg cells) are terminally differentiated lineages with a stable phenotype. However, recent evidence suggests that these cells display plasticity, as observed by the ability to change their pattern of expression of both cytokines and master regulator transcription factors in response to external stimuli, suggesting that apparently fully committed Th cells have a plasticity feature 23, 27 . The role of Treg cells in RA has been reported in both patients and animal models, where the Treg subset represents approximately 5%-10% of the CD4 + T cell population 28 . Increasing evidence suggests that Treg cell function is impaired in chronic inflammatory diseases such as RA. Interestingly, many studies have shown that Tregs directly suppress differentiation into osteoclasts in vitro 29 , and Treg depletion has been shown to aggravate various experimental autoimmune diseases, including collagen-induced arthritis. The underlying mechanism is not fully understood; however, pro-inflammatory cytokines such as TNF-α, IL-6, IL-1β, and IL-21, which are present within the synovial environment, can reduce the suppressive function of Treg cells in vitro 30, 31 . Therefore, the potential for Treg cells to modulate ongoing inflammation in RA remains unclear.
A study by Ehrenstein et al. 32 raises an important question. Is it only a reduction in the number of Treg cells that initiates RA, or is it a qualitative defect in Treg cells that induces the aggressiveness of RA? Ehrenstein et al. 32 have presented evidence suggesting that Treg cells derived from patients with active RA are defective in the ability to suppress cytokine production and to convey a suppressive phenotype to CD4 + effector T cells. They demonstrated that the clinical response to anti-TNF-α therapy, but not conventional therapies, in RA patients, was correlated with an increased number of peripheral blood Treg cells. One possibility is that the presence of TNF-α and other pro-inflammatory cytokines may hinder the ability of Treg cells to prevent autoimmune disease.
Conclusion
In this critical review, we have summarised the progress in our understanding of the role of the cytokines IL-23 and IL-17 and the differentiation of CD4 + T cells into specialised effectors, focusing on Th17 and Treg cells, in the pathogenesis of RA. We conclude that the pathogenesis of RA is slow but complex and that both cytokines and cell-mediated immunity are involved in a complex process that eventually results in irreversible bone and cartilage destruction. Cytokine levels and the Treg/Th17 balance might be relevant to the diversity of clinical manifestations in RA patients and might be critical for the development of improved clinical management and therapeutic options.
Here are some further pointers: • Targeting the IL-23/Th17 axis for drug therapy appears to be a realistic approach to alternative treatments of chronic inflammatory diseases. 
